Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions

Human Reproduction
A NenicuM W Laschke


Is telmisartan effective in the treatment of endometriosis? Combined blockade of angiotensin II type 1 receptor (AT1R) and activation of peroxisome proliferator-activated receptor (PPAR)-γ by telmisartan inhibits vascularization and growth of murine endometriosis-like lesions. AT1R and PPAR-γ are involved in the regulation of inflammation, proliferation and angiogenesis. These processes are also crucial for the pathogenesis of endometriosis and both receptors are expressed in endometrial tissue. Telmisartan is a partial agonist of PPAR-γ, which additionally blocks AT1R. This was a randomized study in the mouse dorsal skinfold chamber and peritoneal model of endometriosis. Endometriosis-like lesions were induced in dorsal skinfold chambers of 21 female C57BL/6 mice, and in the peritoneal cavity of 15 additional animals, which were daily treated with an i.p. injection of pioglitazone (10 mg/kg, n = 12), telmisartan (10 mg/kg, n = 12) or vehicle (5% dimethyl sulfoxide (DMSO), n = 12) throughout an observation period of 14 and 28 days, respectively. The anti-angiogenic actions of pioglitazone, a full PPAR-γ agonist, and telmisartan were firstly assessed in vitro by an aortic ring assay. Endometriosis-like lesions were induced in th...Continue Reading


Jul 19, 1994·Proceedings of the National Academy of Sciences of the United States of America·S A KliewerR M Evans
Jul 19, 2001·The Journal of Biological Chemistry·E D Rosen, B M Spiegelman
Jan 1, 2003·Clinical Chemistry·Robert AuerbachNasim Akhtar
Apr 6, 2005·Biochemical and Biophysical Research Communications·Anja BergerGeorg Nickenig
Oct 8, 2005·Fertility and Sterility·Matthias W LaschkeMichael D Menger
Nov 22, 2005·Life Sciences·Wayne Huey-Herng SheuChing-Hwa Yang
Nov 29, 2005·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Olaf BuchweitzLudwig Kiesel
Dec 28, 2005·Journal of the Society for Gynecologic Investigation·Fazli DemirturkDogan R Koseoglu
Jul 6, 2006·Reproductive Biomedicine Online·Sajal GuptaJuan G Alvarez
Aug 5, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Norihiro NagaiSusumu Ishida
Mar 10, 2007·Human Reproduction Update·Matthias W Laschke, Michael D Menger
Jul 14, 2007·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Hakan AytanDogan R Koseoglu
Oct 19, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Shannon Reagan-ShawNihal Ahmad
Jan 9, 2010·Fertility and Sterility·Daniel Escorsim MachadoLuiz Eurico Nasciutti
Oct 12, 2010·Fertility and Sterility·Jennifer L HeringtonKevin G Osteen
Nov 9, 2010·Annual Review of Physiology·Albert Asante, Robert N Taylor
Dec 1, 2010·Pharmacology & Therapeutics·Andrew MacKenzie
Jan 5, 2011·Frontiers in Bioscience (Elite Edition)·Fuminori TaniguchiTasuku Harada
Mar 4, 2011·British Journal of Pharmacology·M W LaschkeM D Menger
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Cyrus V DesouzaVivian Fonseca
May 19, 2011·Human Reproduction Update·M W LaschkeM D Menger
Jul 23, 2011·Nature Chemistry·Thomas Rauchfuss
Nov 26, 2011·Expert Review of Clinical Pharmacology·Paolo VerdecchiaGianpaolo Reboldi
Feb 23, 2012·Angiogenesis·Dilu FengMatthias W Laschke
Mar 27, 2012·Human Reproduction·J Rudzitis-AuthM W Laschke
Apr 28, 2012·American Journal of Reproductive Immunology : AJRI·Justyna SikoraZdzislawa Kondera-Anasz
May 2, 2012·Archives of Gynecology and Obstetrics·A AugouleaI Lambrinoudaki
Jun 22, 2012·Human Reproduction Update·M W Laschke, M D Menger
Jul 24, 2012·Fertility and Sterility·Richard O Burney, Linda C Giudice

❮ Previous
Next ❯


Apr 10, 2015·Reproduction : the Official Journal of the Society for the Study of Fertility·Panayiota PloutarchouSuzannah A Williams
Oct 11, 2014·The Journal of Obstetrics and Gynaecology Research·Bulent CakmakOytun Erbaş
May 27, 2017·British Journal of Pharmacology·Anca NenicuMatthias W Laschke
Jul 6, 2018·Expert Opinion on Pharmacotherapy·Simone FerreroFabio Barra
Aug 14, 2020·International Journal of Molecular Sciences·Nicole Wagner, Kay-Dietrich Wagner
Jan 30, 2018·Human Reproduction Update·Matthias W Laschke, Michael D Menger
Oct 11, 2017·Angiogenesis·Christina KörbelMatthias W Laschke
Feb 13, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Tingting LiaoZhangye Xu
Dec 24, 2020·Human Reproduction·Nuria PellicerAntonio Pellicer
Jun 19, 2016·The American Journal of Pathology·Jeannette Rudzitis-AuthMatthias W Laschke
May 20, 2021·Minerva Obstetrics and Gynecology·Simona MartoneStefano Luisi
Jul 3, 2021·Pharmaceuticals·Alexandre ValléeYves Lecarpentier

❮ Previous
Next ❯

Related Concepts

Related Feeds


Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.